| Filed On | Filing |
|---|---|
| 07 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of October 6, 2026, is made by and among CERo Therapeutics Holdings, Inc., a Delaware corporation (“Seller”), and SRX Global Inc., a Delaware corporation formerly known as SRX He... |
| 06 Oct 2026 |
8-K: Regulation FD Disclosure
SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim |
| 09 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
This Limited Consent and Amendment Agreement (the “Agreement”), dated as of September 8, 2026, is by and between SRX Global Inc., a Delaware corporation (the “Company”), and the holder identified on the signature page hereto (the “Holder”). |
| 02 Sep 2026 | 8-K: Entry into a Material Definitive Agreement |
| 28 Aug 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities |
| 19 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 13 Aug 2026 | 10-Q |
| 29 Jul 2026 |
8-K/A: Unregistered Sales of Equity Securities
As previously announced, on March 16, 2026, SRX Global Inc. (f/k/a SRx Health Solutions, Inc.), a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accre... |
| 28 Jul 2026 | 8-K: Unregistered Sales of Equity Securities |
| 21 Jul 2026 | 8-K: Entry into a Material Definitive Agreement |
| 16 Jul 2026 | 424B3 |
| 16 Jul 2026 | 424B3 |
| 16 Jul 2026 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 15 Jul 2026 | 8-K: Regulation FD Disclosure |
| 10 Jul 2026 | 8-K: Regulation FD Disclosure |
| 08 Jul 2026 | SCHEDULE 13G/A |
| 06 Jul 2026 | S-8 |
| 26 Jun 2026 | 8-K: Regulation FD Disclosure |
| 25 Jun 2026 | SCHEDULE 13G |
| 24 Jun 2026 | DEFR14C |
Loading...